🔗 Share this article

An underground market for unapproved slimming medications is being driven by social media fitness personalities and vendors on messaging platforms, according to new investigations.

Experimental Drug Gaining Popularity Online

The experimental drug, which is still in research studies, is being advertised by online personalities for its alleged weight-reducing properties. Viewers are encouraged to contact these accounts privately for source information, while also receiving discount codes.

Thriving Commerce on Messaging Platforms

Separately, a flourishing trade exists on Telegram, where groups with numerous of members share comparison photos, injection guides and assertions of rapid UK delivery. Sellers promote the drug there before directing customers to other platforms for purchases.

Understanding Retatrutide

Retatrutide is an experimental injection developed by American pharmaceutical company Eli Lilly. The drug targets three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials suggest it could help patients lose up to 25% of their total weight. Nicknamed the “triple G”, the substance is being hailed digitally as the successor to Ozempic.

Medical Experts Express Concerns

However, doctors and pharmacists have cautions that the distribution of what remains an unapproved medication in the UK is worrisome and could lead to individuals injecting products of uncertain source.

Some experts said the demand for retatrutide could be linked to the rising cost of approved weight loss treatments such as Mounjaro.

Regulatory Status and Enforcement

Selling the unapproved drug on social media or Telegram is illegal in the UK, as it is an unlicensed drug that must not be marketed or supplied for personal consumption under the British medical regulations.

Several influencers attempt to circumvent the rules by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted substance, but advertising and distribution can still violate pharmaceutical, advertising, and customer laws, risking fines, prosecution or imprisonment.

Platform Reaction and Material Elimination

Based on TikTok, the platform has taken down problematic material and prohibited associated keywords and search suggestions. The company stated it was dedicated to maintaining the service secure and allocating resources in strengthening compliance measures.

Online Trading Activities

Research also found groups with up to 9,000 members marketing retatrutide using the platform's integrated search feature, which functions like a online catalog. Entering “retatrutide” immediately brings up channels with thousands of members, filled with photos of slimming results, positive reviews and step-by-step instructions for preparing or injecting at home.

Within minutes of joining one community, a seller posted WhatsApp details, where the majority of transactions occur. The vendor sent an instruction manual and promised delivery within two days. When questioned whether the substance was genuine, one seller responded: “You can’t be sure.” Another provided a photo of a supposed laboratory certificate. None asked about weight, health issues or past usage.

Item Details and Costs

Inside these communities, messages show black plastic packages with Royal Mail stickers, stating to contain fresh supplies. One message stated: “It took eight of us to load them this morning.”

Buyers can choose between dry substance containers, mixed at home with sterile water, or ready-to-use injectors usually sold at £160 for 20 milligrams. When asked how much time a pen should be used, vendors give conflicting responses varying between a few weeks to “depends on your body”.

Platform Oversight and Safety Actions

A representative for Telegram said it actively moderated dangerous content on its service including content that encouraged the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.

Medical Expert Cautions

“Individuals are administering materials they can’t verify. Even if the research behind this drug is sound, these online versions may not include what they claim,” stated Jason Murphy, the director of pharmaceutical services at Chemist4U.

A medical professional of an online medical service linked the surge in interest to recent price rises for approved weight-loss drugs such as Mounjaro. “With prices increasing, patients are turning to social media. But fake treatments are highly dangerous. You cannot know what’s contained or whether the conditions they were produced in was clean,” she explained.

Her team has previously seen patients injured by self-injection from unverified suppliers. “We understand the disappointment, but buying from messaging apps or communication platforms is gambling with your health,” stated Wyllie. “These substances could be contaminated or improperly measured.”

Manufacturer Position

A spokesperson from Eli Lilly said retatrutide was in phase 3 clinical trials and had not been evaluated or authorized by any government authority anywhere in the world. “Therefore at this point no one can sell [it] for human use,” they said, adding that any product “falsely representing itself as a company investigational product not yet approved … may subject patients to possibly significant health risks”.